Adobe's Blockbuster...
Health Care: Drugs
MannKind Corporation (MNKD: NASDAQ)
$7.02 0.42 | 6.28%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.61 |
| 52 Week High | 8.06 |
| 52 Week Low | 1.82 |
| Avg. Daily Vol. (Mil) | 7.64 |
| Beta (3 year) | 1.02 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,921.28 |
| Shares Out (Mil) | 290.88 |
| Float (Mil) | 152.35 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.10 |
| Current Ratio | 0.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 54.89K |
| Price/Book | 0.00 |
| Price/Cash Flow | -12.20 |
| Per Share Data | |
| Earnings | -0.83 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | -0.54 |
| Business Summary | |
|---|---|
| MannKind Corporation is engaged in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. | |
| General Information | |
| 28903 N. Avenue Paine
Valencia, CA 91355 |
|
| www.mannkindcorp.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 246 | |
| CEO: Alfred E. Mann | |
| Short Interest | |
| Current Month (Mil) | 45.98 |
| Previous Month (Mil) | 47.34 |
| Short Interest Ratio (Days) | 5.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -80.00 |
| Return on Investments | 351.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with MNKD
- Portfolio NameUser Type
- ContributorFive Best-Performing Biotec...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- Userbiomed
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserHoldings
Latest MNKD Headlines from TheStreet
- MannKind's Mysterious Lung-Safety Study Is Open But Shhh...Don't Talk About It 04.17.13 | 09:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- 3 Highly Shorted Stocks Under $5 Bought Up By Hedge Funds 04.09.13 | 01:04 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- These 3 Insider Favorites Are Trading Significantly Below Target Price 01.14.13 | 12:01 pm
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
Press Releases for MNKD
- MannKind Corporation To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 05:02 pm
- MannKind Corporation Reports 2012 Fourth Quarter And Full Year Financial Results - Business Wire 02.11.13 | 04:02 pm
- MannKind Corporation To Hold 2012 Fourth Quarter And Full Year Financial Results Conference Call On February 11, 2013 - Business Wire 02.04.13 | 05:02 pm
- MannKind Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 05:01 pm
- MannKind Corporation To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 05:11 pm
- Faruqi & Faruqi, LLP Launches An Investigation Against Mannkind Corp. (MNKD) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors - Business Wire 11.19.12 | 07:11 pm
- Colby And MannKind Sign License And Joint Development Agreement To Develop And Commercialize Cancer Immunotherapy Products - Business Wire 11.13.12 | 08:11 am
- MannKind Corporation Reports 2012 Third Quarter Financial Results - Business Wire 11.01.12 | 04:11 pm
- MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call To November 1, 2012 Due To Hurricane Sandy - Business Wire 10.29.12 | 02:10 pm
- MannKind Corporation To Hold 2012 Third Quarter Financial Results Conference Call On October 29, 2012 - Business Wire 10.22.12 | 06:10 pm
Partner Headlines for MNKD
- This Under-The-Radar Diabetes Stock Has Significant Upside Potential - Seeking Alpha 06.11.13 | 09:06 am
- UPDATE: Bank of America Downgrades on MannKind on Valuation - Benzinga 06.07.13 | 09:06 am
- Social Networking Stocks Faltering And The Volatile Biotechs - Seeking Alpha 06.04.13 | 09:06 am
- Afternoon Market Gainers - Benzinga 06.03.13 | 01:06 pm
- MannKind Closes Phase 3 Study of AFREZZA for Type 1 Diabetes - Benzinga 05.31.13 | 04:05 pm
- Market Wrap for Wednesday, May 22: Stocks Pullback As Bernanke Says Bond Buying Could Slow - Benzinga 05.22.13 | 04:05 pm
- Mid-Afternoon Market Update: MannKind Posts Huge Rally as Markets Plummet - Benzinga 05.22.13 | 04:05 pm
- U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying - Benzinga 05.18.13 | 03:05 pm
- Why MannKind's Afrezza Will Succeed Where Pfizer Failed - Seeking Alpha 05.18.13 | 04:05 am
- Mid-Afternoon Market Update: Markets Remain Down, Bankrate Rallies - Benzinga 04.12.13 | 03:04 pm
